A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Second-Line Treatment in Patients With Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Tasisulam (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 19 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.